BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 66 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $219,222 | -43.2% | 76,384 | 0.0% | 0.00% | – |
| Q2 2023 | $385,739 | +167.2% | 76,384 | 0.0% | 0.00% | – |
| Q1 2023 | $144,366 | -47.5% | 76,384 | -50.0% | 0.00% | – |
| Q4 2022 | $274,982 | +113.2% | 152,768 | +100.0% | 0.00% | – |
| Q3 2022 | $129,000 | -31.4% | 76,384 | 0.0% | 0.00% | – |
| Q2 2022 | $188,000 | -81.6% | 76,384 | -79.3% | 0.00% | – |
| Q1 2022 | $1,023,000 | -47.4% | 369,262 | +1.3% | 0.00% | – |
| Q4 2021 | $1,944,000 | -35.4% | 364,653 | +2.5% | 0.00% | – |
| Q3 2021 | $3,009,000 | -26.2% | 355,703 | +6.4% | 0.00% | – |
| Q2 2021 | $4,076,000 | -90.6% | 334,351 | -81.4% | 0.00% | -100.0% |
| Q1 2021 | $43,538,000 | +65.1% | 1,794,638 | +118.2% | 0.00% | 0.0% |
| Q4 2020 | $26,365,000 | +212.7% | 822,617 | +194.9% | 0.00% | +100.0% |
| Q3 2020 | $8,432,000 | -13.1% | 278,919 | +21.2% | 0.00% | 0.0% |
| Q2 2020 | $9,702,000 | +105.7% | 230,118 | +21.7% | 0.00% | – |
| Q1 2020 | $4,716,000 | – | 189,023 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Boxer Capital, LLC | 2,014,858 | $17,046,000 | 0.60% |
| NEA Management Company, LLC | 3,449,845 | $29,186,000 | 0.35% |
| MPM BioImpact LLC | 248,506 | $2,102,000 | 0.33% |
| Artal Group S.A. | 1,646,517 | $13,930,000 | 0.31% |
| RA Capital Management | 2,589,904 | $21,911,000 | 0.30% |
| Bellevue Group AG | 3,463,000 | $29,297,000 | 0.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 760,128 | $6,431,000 | 0.13% |
| Ikarian Capital, LLC | 150,484 | $1,272,000 | 0.09% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 44,000 | $371,000 | 0.09% |
| Virtus ETF Advisers LLC | 16,600 | $140,000 | 0.06% |